Desmopressin Acetate Solution
NDC Package 69918-901-11
Package Information
Desmopressin Acetate solution is desmopressin acetate injection is contraindicated in patients with known hypersensitivity to desmopressin acetate or to any of the components of desmopressin acetate injection [see Warnings and Precautions (5.4), Adverse Reactions (6), Description (11)].Desmopressin acetate injection is contraindicated in patients with the following conditions due to an increased risk of hyponatremia:Moderate to severe renal impairment defined as a creatinine clearance below 50 mL/min [see Use in Specific Populations (8.5, 8.6) and Clinical Pharmacology (12.3)].Hyponatremia or a history of hyponatremia [see Warnings and Precautions (5.1), Drug Interactions (7.1)], Use in Specific Populations (8.4, 8.5)].Known or suspected syndrome of inappropriate antidiuretic hormone (SIADH) secretion [see Warnings and Precautions (5.1)].Polydipsia [see Warnings and Precautions (5.1)].Concomitant use with loop diuretics [see Boxed Warning].Concomitant use with systemic or inhaled glucocorticoids [see Boxed Warning].During illnesses that can cause fluid or electrolyte imbalance, such as gastroenteritis, salt-wasting nephropathies, or systemic infection [see Boxed Warning].Desmopressin acetate injection is contraindicated in patients with the following conditions because fluid retention increases the risk of worsening the underlying condition:Heart failureUncontrolled hypertension. This formulation utilizes a solution delivery system. Marketed by Nordic Pharma, Inc., this product is identified by NDC 69918-901 and is authorized under FDA application NDA018938.
Identification & Billing
- RxCUI: 1723232 - desmopressin acetate 4 MCG in 1 ML Injection
- RxCUI: 1723232 - 1 ML desmopressin acetate 0.004 MG/ML Injection
- RxCUI: 1723232 - desmopressin acetate 4 MCG per 1 ML Injection
- RxCUI: 849501 - desmopressin acetate 4 MCG/ML Injectable Solution
- RxCUI: 849501 - desmopressin acetate 0.004 MG/ML Injectable Solution
Clinical Specifications
- Intravenous - Administration within or into a vein or veins.
- Intravenous - Administration within or into a vein or veins.
- Intravenous - Administration within or into a vein or veins.
- Factor VIII Activator - [EPC] (Established Pharmacologic Class)
- Increased Coagulation Factor VIII Activity - [PE] (Physiologic Effect)
- Increased Coagulation Factor VIII Concentration - [PE] (Physiologic Effect)
- Vasopressin Analog - [EPC] (Established Pharmacologic Class)
- Vasopressins - [CS]
- Factor VIII Activator - [EPC] (Established Pharmacologic Class)
- Increased Coagulation Factor VIII Activity - [PE] (Physiologic Effect)
- Increased Coagulation Factor VIII Concentration - [PE] (Physiologic Effect)
- Vasopressin Analog - [EPC] (Established Pharmacologic Class)
- Vasopressins - [CS]
- Factor VIII Activator - [EPC] (Established Pharmacologic Class)
- Increased Coagulation Factor VIII Activity - [PE] (Physiologic Effect)
- Increased Coagulation Factor VIII Concentration - [PE] (Physiologic Effect)
- Vasopressin Analog - [EPC] (Established Pharmacologic Class)
- Vasopressins - [CS]
Regulatory & Marketing
Hierarchy Structure
- 69918 - Nordic Pharma, Inc.
- 69918-901 - Desmopressin Acetate
- 69918-901-11 - 1 VIAL, MULTI-DOSE in 1 CARTON / 10 mL in 1 VIAL, MULTI-DOSE
- 69918-901 - Desmopressin Acetate
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (69918-901). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69918-901-11 identifies a specific commercial package of 1 vial, multi-dose in 1 carton / 10 ml in 1 vial, multi-dose of Desmopressin Acetate, a human prescription drug labeled by Nordic Pharma, Inc.. This solution is formulated for intravenous use and contains desmopressin acetate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Nordic Pharma, Inc. on January 20, 2016. The current certification is valid through December 31, 2027.
How is this Nordic Pharma, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69918090111. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 10 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.
